15:23:06 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriLäkemedel & Handel
DanCann Pharma grundades 2018 och är ett danskt läkemedelsbioteknikbolag som drivs av cannabinoider. DanCann Pharma fokuserar på att upptäcka, utveckla, tillverka och kommersialisera nya cannabinoida läkemedel inom ett brett spektrum av sjukdomsområden. Bolaget tillverkar och distribuerar receptbelagda läkemedel och receptfria läkemedel (OTC), främst fokuserade på smärtpatienter med alternativa behov och hantering av sin sjukdom, täckta av det danska pilotprogrammet för medicinsk cannabis.

Kalender

2022-04-07 Årsstämma 2022
2022-02-25 Bokslutskommuniké 2021
2021-11-26 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-07-23 Extra Bolagsstämma 2021
2021-05-28 Kvartalsrapport 2021-Q1
2021-04-29 Ordinarie utdelning DANCAN 0.00 DKK
2021-04-28 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2021-07-27 11:30:00

COPENHAGEN, Denmark, 27 July 2021 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company") hereby announces that Jeppe Krog Rasmussen, Founder, Board Member and CEO at DanCann Pharma A/S has privately through his holding company (Xignotus Capital ApS) subscribed for 267,023 new shares, equivalent to a subscription amount of DKK 1,000,001.135, and 267,023 warrants in DanCann Pharma A/S and John Morell Frellsen has privately trough his holding company (Morellco Holding ApS) subscribed for 25,000 new shares, equivalent to a subscription amount of DKK 93,625, as well as 25,000 warrants.

The shares and warrants were subscribed for in the directed issue at the extraordinary general meeting on 23 July 2021, and the shares was subscribed for at market price, being DKK 3.745 per share, whereas the warrants were subscribed for free of charge. In accordance with the new Schedule 7.1 of the articles of association, each warrant gives the right to subscribe for 1 share of nominally DKK 0.0375 at an exercise price of DKK 4.8685.

Following this transaction, Jeppe Krog Rasmussen now directly through his holding company (Xignotus Capital ApS) owns 5,747,023 shares, corresponding to approx. 25.62 percent (26.43 percent before) in total at DanCann Pharma, while John Morell Frellsen through his holding company Morellco Holding ApS owns 145,001 shares, corresponding to approx. 0.64 percent (0.57 percent before).

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution Company based in Denmark. The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen.
For more information, visit: www.dancann.com

For further information, please contact:

Jeppe Krog Rasmussen, CEO
E-mail: jkr@dancann.com
Website: www.dancann.com